Pfizer Inc. (NYSE:PFE) Shares Sold by Front Row Advisors LLC

Front Row Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 32.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,127 shares of the biopharmaceutical company’s stock after selling 1,971 shares during the quarter. Front Row Advisors LLC’s holdings in Pfizer were worth $109,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Pfizer in the 4th quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $274,694,000. Fisher Asset Management LLC raised its stake in shares of Pfizer by 79.5% during the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after buying an additional 4,938,209 shares during the period. Finally, Van ECK Associates Corp lifted its position in shares of Pfizer by 28.5% during the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after buying an additional 4,726,549 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $25.36 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $143.80 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm’s 50-day moving average is $26.05 and its two-hundred day moving average is $26.88. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.